Gilead CEO Says Over 50,000 Remdesivir Courses Ready to Ship

(Bloomberg) -- Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said there are more than 50,000 courses of the company’s experimental Covid-19 therapy, packed in vials and ready to ship as...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.